neuroendocrine

Graphic image of a red thumbs down against a blue background
Favicon Fierce Pharma

ITM cancer drug spurned by FDA over manufacturing qualms

The problems lie not with ITM-11's efficacy or safety but with its CMC and with a third-party commercial facility.
Darren Incorvaia Aug 10, 2026 11:25am
radiopharma radiopharmaceuticals

Sanofi $110M radioligand therapy hits main goal in ph. 2 trial

Oct 8, 2025 6:25am
radiopharmaceutical radiotherapeutic

Sanofi pays $110M upfront for late-stage radioligand therapy

Sep 12, 2024 4:54am
bowel

Crinetics growth disorder drug sees ph. 2 carcinoid syndrome win

Mar 13, 2024 9:16am
This is a photo of the Clinical Research Building of the Perelman School of Medicine at the University of Pennsylvania in Phi

Carl June's latest CAR-T work taps llamas for GI cancers

Mar 29, 2022 9:00am
Chi-Med CEO Christian Hogg

Chi-Med's surufatinib fends off pancreatic tumors in phase 3

Sep 18, 2020 6:05pm